|
| |
BioPortfolio's Approved Drugs DatabaseEmendFosaprepitant DimeglumineDownload PDF containing detailed information.
Press Releases About Emend:
|
 |
| The Cancer Market Outlook to 2009 |
1st January, 1970 |
Datamonitor |
The
Cancer Market Outlook to 2009
This report quantifies the patient potential in
different cancer sub-markets and provides benchmarks for new cancer drug
development and marketing strategies;
|
Companies working in the area of Emend from Bioportfolio's Biocorporate database : |  |
| Company Name | |
Why Outsource Development Services to ABC Laboratories?
As a mid-sized service provider, ABC Laboratories offers its clients the regulatory compliance, technical skill and modern...
www.abclabs.com/ View full profile
| |
Active Biotech develops innovative pharmaceuticals that modulate the body's own immune system. We focus on widespread diseases for which a tremendous need is felt for new and more effective treatments...
www.actin.co.uk/ View full profile
| |
CellGate engages in the discovery and development of an array of revolutionary "transporter molecules" that can be attached to any small molecule or macromolecular drug. Modification of a drug with...
www.cell.com/ View full profile
| | →View more Emend related companies. |
This page has been viewed 22 times
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Emend across BioPortfolio, or for Emend Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|